221 related articles for article (PubMed ID: 28712306)
21. Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.
Yu L; Liu S
Semin Cancer Biol; 2013 Dec; 23(6 Pt B):553-60. PubMed ID: 24012660
[TBL] [Abstract][Full Text] [Related]
22. Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies.
Jullien M; Gomez-Bougie P; Chiron D; Touzeau C
Cells; 2020 Mar; 9(3):. PubMed ID: 32183335
[TBL] [Abstract][Full Text] [Related]
23. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
Merino D; Lok SW; Visvader JE; Lindeman GJ
Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
[TBL] [Abstract][Full Text] [Related]
24. Targeting the B-cell lymphoma 2 anti-apoptotic proteins for cervical cancer treatment.
Abdul Rahman SF; Xiang Lian BS; Mohana-Kumaran N
Future Oncol; 2020 Oct; 16(28):2235-2249. PubMed ID: 32715755
[TBL] [Abstract][Full Text] [Related]
25. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
Panayotopoulou EG; Müller AK; Börries M; Busch H; Hu G; Lev S
Oncotarget; 2017 Jul; 8(28):45088-45104. PubMed ID: 28187446
[TBL] [Abstract][Full Text] [Related]
26. Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia.
Billard C
Leukemia; 2012 Sep; 26(9):2032-8. PubMed ID: 22453662
[TBL] [Abstract][Full Text] [Related]
27. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.
Abed MN; Abdullah MI; Richardson A
J Ovarian Res; 2016 Apr; 9():25. PubMed ID: 27080533
[TBL] [Abstract][Full Text] [Related]
28. Multifaceted anticancer activity of BH3 mimetics: Current evidence and future prospects.
Opydo-Chanek M; Gonzalo O; Marzo I
Biochem Pharmacol; 2017 Jul; 136():12-23. PubMed ID: 28288819
[TBL] [Abstract][Full Text] [Related]
29. [BH3 mimetics as a strategy to complement anticancer therapies].
Hartman MŁ; Czyż M
Postepy Hig Med Dosw (Online); 2012 Feb; 66():67-77. PubMed ID: 22371408
[TBL] [Abstract][Full Text] [Related]
30. Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer.
Guikema JE; Amiot M; Eldering E
Expert Opin Ther Targets; 2017 Aug; 21(8):767-779. PubMed ID: 28670929
[TBL] [Abstract][Full Text] [Related]
31. Novel Mcl-1/Bcl-2 dual inhibitors created by the structure-based hybridization of drug-divided building blocks and a fragment deconstructed from a known two-face BH3 mimetic.
Zhang Z; Su P; Li X; Song T; Chai G; Yu X; Zhang K
Arch Pharm (Weinheim); 2015 Feb; 348(2):89-99. PubMed ID: 25641608
[TBL] [Abstract][Full Text] [Related]
32. Hypericin, a potential new BH3 mimetic.
Doroshenko A; Tomkova S; Kozar T; Stroffekova K
Front Pharmacol; 2022; 13():991554. PubMed ID: 36267274
[TBL] [Abstract][Full Text] [Related]
33. Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling.
Grundy M; Seedhouse C; Jones T; Elmi L; Hall M; Graham A; Russell N; Pallis M
PLoS One; 2018; 13(1):e0190682. PubMed ID: 29298347
[TBL] [Abstract][Full Text] [Related]
34. Anticancer effects of putative and validated BH3-mimetic drugs in head and neck squamous cell carcinomas: An overview of current knowledge.
Melo G; Silva CAB; Hague A; Parkinson EK; Rivero ERC
Oral Oncol; 2022 Sep; 132():105979. PubMed ID: 35816876
[TBL] [Abstract][Full Text] [Related]
35. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
Alford SE; Kothari A; Loeff FC; Eichhorn JM; Sakurikar N; Goselink HM; Saylors RL; Jedema I; Falkenburg JH; Chambers TC
Cancer Res; 2015 Apr; 75(7):1366-75. PubMed ID: 25649768
[TBL] [Abstract][Full Text] [Related]
36. BH3 mimetics efficiently induce apoptosis in mouse basophils and mast cells.
Reinhart R; Rohner L; Wicki S; Fux M; Kaufmann T
Cell Death Differ; 2018 Jan; 25(1):204-216. PubMed ID: 28960207
[TBL] [Abstract][Full Text] [Related]
37. BH3-only protein BIM: An emerging target in chemotherapy.
Shukla S; Saxena S; Singh BK; Kakkar P
Eur J Cell Biol; 2017 Dec; 96(8):728-738. PubMed ID: 29100606
[TBL] [Abstract][Full Text] [Related]
38. Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck.
Carter RJ; Milani M; Butterworth M; Alotibi A; Harper N; Yedida G; Greaves G; Al-Zebeeby A; Jorgensen AL; Schache AG; Risk JM; Shaw RJ; Jones TM; Sacco JJ; Hurlstone A; Cohen GM; Varadarajan S
Cell Death Dis; 2019 Dec; 10(12):912. PubMed ID: 31801952
[TBL] [Abstract][Full Text] [Related]
39. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD
Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547
[TBL] [Abstract][Full Text] [Related]
40. Targeting BCL-2-like Proteins to Kill Cancer Cells.
Cory S; Roberts AW; Colman PM; Adams JM
Trends Cancer; 2016 Aug; 2(8):443-460. PubMed ID: 28741496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
